– USA, MA – CAMP4 Therapeutics Corporation (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide therapies, announced the appointments of Dr. Doug Williams (Ph.D.), and Dr. Murray Stewart (DM FRCP) to its Board of Directors.
About Dr. Doug E. Williams
With over 30 years in the biopharma industry, Dr. Doug Williams has contributed to the development of several transformative drugs, including LEUKINE, ENBREL, ADCETRIS, TECFIDERA, APROLIX, ELOCTATE, and SPINRAZA. He was previously President of R&D at Sana Biotechnology and the Founding President & CEO of Codiak BioSciences. Before Sana, Dr. Doug Williams served as EVP of R&D at Biogen, and earlier in his career was CEO of ZymoGenetics, and held leadership roles at Seattle Genetics, Amgen, and Immunex. Throughout his career, he has served on the Board of Directors and Advisory Boards of more than two dozen biotech companies.
About Dr. Murray Stewart
Dr. Murray Stewart serves as a Senior Medical Advisor to several biopharma companies and was most recently CMO at Rhythm Pharmaceuticals. Before this position, he served as Head of R&D at Novelion Therapeutics. Before joining Novelion, he served as corporate CMO at GlaxoSmithKline. With extensive clinical development experience, he has led studies across all stages, from first-in-human trials to large Phase 4 cardiovascular outcome studies. Dr. Stewart has played a key role in the successful registration and launch of multiple therapies, including AVANDIA, ARIXTRA, TANZEUM, and XOLREMDI. Before transitioning to industry, he served as a Consultant Physician and Head of Clinical Services at the Diabetes Centre in Newcastle upon Tyne, UK, where his research was focused on lipid metabolism and type 2 diabetes.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful.
For more information: https://www.camp4tx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.